Tenax Q1 net loss $15.7M; cash $118.8M; Phase 3 topline data expected Q3 2026

TENAX THERAPEUTICS, INC.

2026-Q1 EPS reported -$0.35 vs consensus -$0.41 ▲ beat (+14.2%)

Net loss of $15.7M for Q1 2026 vs $10.4M in Q1 2025; R&D expense rose to $11.5M from $5.7M.
Cash and equivalents $118.8M as of March 31, 2026; expected to fund operations through at least Q1 2028.
Phase 3 LEVEL study fully randomized (>230 patients); topline data anticipated in Q3 2026.
Appointed Thomas Staab as CFO, Timothy Healey as CCO, and So-Young Kim as EVP Clinical Development.
Phase 3 LEVEL-2 trial ongoing; enrollment completion expected by end of 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TENAX THERAPEUTICS, INC. reported the quarter ended March 31, 2026 results: net income $15.7 million.

Period: the quarter ended March 31, 2026
Net income: $15.7 million
Result: reported results

Exact text from the filing

Tenax Therapeutics reported a net loss of $15.7 million for the first quarter of 2026, compared to a net loss of $10.4 million for the first quarter of 2025.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-218224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.